KPR Antibody

Ketopantoate Reductase (KPR) Overview

KPR is a bacterial enzyme in the CoA biosynthesis pathway, essential for Staphylococcus aureus survival. It catalyzes the NADPH-dependent reduction of ketopantoate to pantoate . Structural studies reveal:

• Dimeric structure: S. aureus KPR forms a stable dimer, unlike its monomeric E. coli counterpart .

• Key residues: Mutations at Glu 194 and Phe 279 destabilize dimerization, impairing enzymatic activity .

KPR as a Drug Target

KPR inhibition disrupts bacterial metabolism, leading to cell death. Key research findings include:

Table 1: Experimental Mutagenesis Effects on S. aureus KPR

Table 2: Kinetic Properties of S. aureus KPR

Therapeutic Strategies Targeting KPR

While no direct "KPR antibodies" are documented, small-molecule inhibitors and substrate analogs have been explored:

• CJ-15,801: A pantothenic acid analog that inhibits CoA biosynthesis upstream of KPR .

• Mutagenesis-driven destabilization: Disrupting dimer integrity via Glu 194 or Phe 279 mutations reduces enzymatic efficiency, validating KPR as a target .

Antibody Contextual Analysis

Antibody development against bacterial enzymes like KPR would require:

• Epitope specificity: Targeting conserved regions (e.g., dimer interface residues Glu 194/Phe 279) .

• Functional assays: Native-PAGE or thermal shift assays to validate antibody-induced structural disruption .

Notably, commercial antibody databases (e.g., Biocompare, antibodies-online) list no products for "KPR Antibody," reinforcing the absence of such reagents in current research .

Research Gaps and Future Directions

1. Antibody feasibility: No studies have reported monoclonal or polyclonal antibodies against KPR.

2. Alternative approaches: Prioritize small-molecule inhibitors over antibodies due to KPR's intracellular localization and enzymatic mechanism.

3. Structural insights: Cryo-EM or X-ray crystallography of KPR-inhibitor complexes could guide rational drug design .